Long-lasting response with lapatinib treatment: a case report

Lapatinib is a small molecule and a reversible inhibitor of HER2, which has shown to be effective on brain lesions in patients with HER2-positive breast cancer relapsed at the central nervous system (CNS). We report the clinical case of a young woman, treated with the combination of lapatinib and capecitabine from September 2009 to today for a metastatic recurrence of HER2-positive breast carcinoma at CNS level and who has achieved a complete response of the encephalic lesion and has not shown disease progression at systemic or CNS level, with excellent tolerance profile (Oncology).